# A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

> **NCT05198817** · PHASE1 · UNKNOWN · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Advanced Malignant Tumors

## Interventions

- **DRUG:** SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection

## Key facts

- **NCT ID:** NCT05198817
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-02-22
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-06-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2022-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05198817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05198817, "A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05198817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*